Overview

Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)

Status:
Completed

Trial end date:
2018-09-01

Target enrollment:

Participant gender:

Summary

(-)-Epicatechin will be evaluated for the treatment of progressive muscle loss and impaired skeletal muscle function in Becker Muscular Dystrophy (BMD) patients.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Craig McDonald, MD

Collaborator:

Cardero Therapeutics, Inc.